Products & Services · Maximum funding

HELIOS-B Phase 3 Clinical Trial — Maximum funding

Alnylam Pharmaceuticals HELIOS-B Phase 3 Clinical Trial — Maximum funding remained flat by 0.0% to $70.00M in Q1 2026 compared to the prior quarter.

Analysis

StatementSegment
First reportedQ3 2020
Last reportedQ1 2026
Metric ID: alny_segment_helios_b_phase_3_clinical_trial_maximum_funding

Historical Data

2 periods
 Q4 '25Q1 '26
Value$70.00M$70.00M
QoQ Change—+0.0%
Range$70.00M – $70.00M

Frequently Asked Questions

What is Alnylam Pharmaceuticals's helios-b phase 3 clinical trial — maximum funding?
Alnylam Pharmaceuticals (ALNY) reported helios-b phase 3 clinical trial — maximum funding of $70.00M in Q1 2026.